title: Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
abstract: The relationship between duration of treatment and biochemical parameters reflecting antiosteoclastic activity was studied in 26 patients with Paget's disease of bone receiving Cl2MDP 1600 mg/day. Six months after initiation of therapy, the reduction in total urinary hydroxyproline was not different in patients treated for 1, 3, 5, or 6 months. This remission lasted 1 year for all groups. In contrast, the longest treatment induced the greatest reduction in serum alkaline phosphatase. One year after the initiation of therapy, this reduction was sustained, whereas a slight relapse was noted in other groups. From these findings, it appears that a rapid bone load with oral Cl2MDP can induce a long-lasting reduction in bone resorption excess.
mesh_terms: D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D004002:Clodronic Acid / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors
chemical_list: D004164:Diphosphonates; D004002:Clodronic Acid; D000469:Alkaline Phosphatase; D006909:Hydroxyproline